Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

This study is testing a new experimental drug, RMC-5127, to see how safely it can treat advanced solid tumors that have a specific genetic change called a KRAS G12V mutation. The goal is to see if this new treatment, alone or paired with other medications, can effectively slow down or shrink cancer growth.

You may be eligible if you are 18 or older, have an advanced solid tumor like lung, colon, or pancreatic cancer with the KRAS G12V mutation, and have already tried other standard treatments. You must also be physically able to manage daily tasks and attend regular clinic appointments.

Participants will receive the study medication and undergo regular health check-ups, including medical imaging like CT or MRI scans, to monitor how the cancer is responding. The medical team will closely observe you to ensure the treatment is well-tolerated and to track any side effects.

The study is currently recruiting patients at medical centers in New Haven, Connecticut; Baltimore, Maryland; and Boston, Massachusetts. Since it is an active trial, you should talk to your doctor to see if one of these locations is a good fit for you.